Natera launches melanoma trial as Citi lifts Natera stock target to USD 480.00

Published on 10/07/2026 at 15:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter loss per share was USD 0.47 versus USD 0.49 expected. Natera stock costs EUR 352.90 on October 7, 2026 after EUR 355.80.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) was trading at EUR 352.90 at Lang & Schwarz on October 7, 2026 at 3:34 p.m. CEST, down 0.82 percent versus the prior close of EUR 355.80. On October 7, Business Wire reported that Natera had enrolled the first patients in a new Signatera-guided melanoma trial, while Markets Insider reported on October 6 that Citi lifted its price target from USD 365.00 to USD 480.00 and kept a Buy rating.

Signatera expands its clinical role

The trial uses Signatera to identify persistent molecular residual disease before radiographic progression in patients with advanced or metastatic melanoma. After six weeks of first-line treatment, Signatera-positive patients without radiographic progression will be randomized between continued treatment and intensified therapy, with progression-free survival as the primary endpoint, according to Business Wire.

For Natera, the study adds a prospective clinical application to Signatera beyond monitoring. The commercial payoff remains tied to validation, adoption and reimbursement, so the trial design matters more than enrollment alone.

Revenue outpaced expectations

Natera's second-quarter 2026 revenue reached USD 752.75 million, up 37.70 percent from the prior year and above the USD 661.24 million analyst expectation, according to MarketBeat. The company reported a USD 0.47 loss per share, narrower than the USD 0.49 consensus loss.

The figures show the current investment tension: revenue growth is running well ahead of expectations, but the business remains loss-making. Citi's USD 480.00 target is also materially above its prior USD 365.00 level, reflecting the importance of Signatera momentum and Natera's women health and organ health operations.

Stock stays below its prior close

Natera stock was trading at EUR 352.90 at Lang & Schwarz on October 7, 2026 at 3:34 p.m. CEST, down 0.82 percent versus the Lang & Schwarz prior close of EUR 355.80 on October 6, 2026. The primary listing is on NASDAQ, where the finance quote showed USD 389.70 at 9:41 a.m. ET on October 7, 2026; the 52-week range was USD 167.99 to USD 437.41 and market capitalization was USD 55.8 billion.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.